Plasma Derived Medicine Market Size, Share, Growth, and Industry Analysis, By Types (Albumin, Immune Globulin, Coagulation Factor, Others) , Applications (Bleeding Wound, Immunodeficiency, HBV, Tetanus, Rabies, Hemophilia, Others) and Regional Insights and Forecast to 2033

Plasma Derived Medicine Market Size

The global Plasma Derived Medicine Market Size was valued at USD 2,662.45 million in 2024 and is projected to reach USD 2,870.12 million in 2025, expanding to USD 5,234.2 million by 2033. The market is forecasted to grow at a CAGR of 7.8% during the forecast period (2025-2033), driven by increasing demand for plasma-based therapies, rising prevalence of rare diseases, and advancements in plasma fractionation technology.

The US Plasma Derived Medicine Market Size is seeing strong growth due to increased investment in biotechnology, rising plasma donations, and growing awareness of immunodeficiency and bleeding disorders. The expanding use of plasma-derived products in treating neurological, hematological, and autoimmune diseases is further fueling market expansion in the US.

The Plasma Derived Medicine market is witnessing rapid growth due to increasing usage of immunoglobulins, albumin, and clotting factors. Over 80% of these medicines are used in treating chronic conditions and immune-related diseases. The plasma derived medicine market in developed regions contributes over 65% of total global usage.

Plasma collection centers have increased by over 30% globally in the past five years. More than 75% of plasma derived medicine demand originates from hospitals and specialty clinics. The adoption rate of plasma therapies has surged by over 40% since 2020, making the plasma derived medicine market a fast-evolving segment in biopharmaceuticals.

Plasma Derived Medicine Market Trends 

The plasma derived medicine market is shaped by a number of emerging trends, particularly the rising global dependence on plasma-based therapies. Immunoglobulins dominate the market, accounting for over 45% of total plasma product consumption. Albumin follows with over 35% share, largely driven by Asia-Pacific, where demand has grown by more than 60% in recent years.

Clotting factors represent over 20% of plasma medicine applications, with a usage increase of over 50% in hemophilia treatment protocols. Global plasma donations have increased by over 70%, contributing to improved access and stability of plasma supply chains.Plasma collection centers have expanded by 25% globally since 2021, while automation in plasmapheresis has improved plasma yield by over 30%. Over 65% of the therapies approved for rare diseases between 2022 and 2024 were plasma-based.

Patient dependency on plasma-derived immunotherapies has surged by more than 55% in chronic neurological and autoimmune conditions. Furthermore, investment in R&D for plasma technologies has increased by over 40%, especially in purification and fractionation processes. Digitally integrated logistics systems now manage over 50% of plasma product distribution, improving traceability and reducing delays. The plasma derived medicine market continues evolving with over 35% of manufacturers expanding capacity between 2020 and 2024.

Plasma Derived Medicine Market Dynamics

The plasma derived medicine market is driven by a dynamic combination of medical need, donor availability, and therapeutic effectiveness. Over 70% of chronic immune disorder treatments now involve plasma-derived drugs. Plasma-based therapies are involved in over 60% of treatment regimens for rare and orphan diseases. Advances in collection technology have led to a 40% improvement in processing efficiency. Moreover, over 50% of pharmaceutical companies working in biologics have entered or expanded into the plasma derived medicine segment. With a 65% increase in product approvals between 2020 and 2024, the plasma derived medicine market is becoming more innovation-driven and competitive.

DRIVER

"Increasing Demand for Immunoglobulins and Plasma Therapies"

The primary driver for the plasma derived medicine market is the rising global use of immunoglobulins, now making up over 60% of all plasma-derived therapeutics. Patient demand has risen by over 70% in the past five years, especially for treating immunodeficiencies and autoimmune diseases. The elderly population, which contributes to over 35% of immunoglobulin usage, is growing steadily. Furthermore, over 55% of neurological disorder cases are being managed using IVIG therapy. Awareness campaigns have boosted treatment adoption by 45% since 2020. These factors have driven over 50% of market participants to focus on immunoglobulin R&D and production capacity expansion.

RESTRAINT

"Limited Plasma Collection Infrastructure and High Cost "

Despite growth, the plasma derived medicine market faces key restraints. Over 60% of developing nations lack sufficient plasma collection centers. More than 40% of total plasma used globally is imported, reflecting heavy dependence on few regions. Operational costs have risen by over 35% due to complex testing and validation processes. Plasma wastage during collection and storage exceeds 20%, creating inefficiencies. Regulatory burdens contribute to over 30% of total production delays. Additionally, workforce shortages in collection facilities have impacted capacity by over 25%. These challenges restrict over 50% of small manufacturers from scaling in the plasma derived medicine market.

OPPORTUNITY

"Growth in Rare Disease Diagnosis and Orphan Drug Development "

A major opportunity lies in rare disease treatment, with over 80% of such conditions lacking effective therapies. Plasma derived medicine is now part of over 65% of treatment plans for rare diseases. Orphan drug designations for plasma-based therapies have grown by over 30% from 2020 to 2024. Diagnostic rates for rare diseases have improved by over 50%, increasing the target patient population. Over 40% of biotech firms are focusing on plasma-derived biologics. Clinical trials involving plasma medicines have increased by 45%, with more than 60% showing positive efficacy results. This momentum is opening new doors in the plasma derived medicine market.

CHALLENGE

"Complex Manufacturing Process and Regulatory Barriers "

The plasma derived medicine market faces substantial challenges, primarily in manufacturing and regulation. The production cycle spans over 12 months, with over 60% of that time dedicated to purification and validation. Over 45% of firms report difficulties aligning with international quality standards. Manufacturing costs have risen by over 30% due to increased quality control measures. Regulatory approvals are delayed in over 35% of cases due to non-harmonized global standards. Distribution of plasma products is limited in over 40% of low-income regions. Combined, these issues affect over 50% of the supply chain, challenging timely availability of plasma derived medicine.

Segmentation Analysis

The plasma derived medicine market is segmented by type and application, with each sub-category contributing distinct % shares. By type, albumin represents over 35%, immune globulin dominates with more than 45%, coagulation factors hold over 15%, and other plasma products contribute nearly 5%. By application, immunodeficiency accounts for over 40%, hemophilia makes up 25%, bleeding wound care over 10%, HBV over 8%, and tetanus and rabies combined contribute more than 12%. “Others” hold around 5%. Collectively, these segments shape the plasma derived medicine market dynamics with varied % trends across global healthcare applications.

By Type 

• Albumin: Albumin contributes over 35% of the total plasma derived medicine market share. Its usage has increased by more than 30% since 2020, with emergency and surgical procedures driving over 60% of demand. Asia-Pacific alone accounts for over 45% of albumin consumption globally. Over 25% of hospital-based treatments now include albumin infusion. Adoption in liver failure cases accounts for more than 55% of usage. With therapeutic improvements and procedural adoption rates increasing by over 40%, albumin remains one of the fastest-rising products within the plasma derived medicine market.
• Immune Globulin: Immune globulin holds the largest share of the plasma derived medicine market, contributing more than 45%. IVIG usage has increased by over 50%, and over 70% of immunodeficient patients are treated using immune globulin. Subcutaneous usage now accounts for over 30% of total immune globulin administration. Demand from pediatric and geriatric populations has surged by over 40%, while autoimmune treatments using immune globulin have grown by over 55%. North America alone consumes over 65% of the global immune globulin supply, showing regional dominance within this plasma derived medicine market type.
• Coagulation Factor: Coagulation factors represent over 15% of the global plasma derived medicine market. Hemophilia therapies account for more than 80% of coagulation factor use. Factor VIII dominates this segment with over 60% share among coagulation therapies. Patient reliance on clotting factors has risen by more than 35%, with hospital-based use growing by over 45%. Clinical trials targeting coagulation factor development have increased by over 25%, while production capacity among manufacturers has expanded by more than 20%. These factors drive consistent growth within the coagulation segment of the plasma derived medicine market.
• Others: The “Others” category in the plasma derived medicine market contributes nearly 5% and includes antithrombin III, fibrin sealants, and specialty plasma proteins. More than 50% of their applications are in surgical or transplant procedures. Usage in trauma care has grown by over 30%, and sepsis treatment contributes to over 20% of demand. Over 10% of R&D efforts are now directed at these niche therapies. Their adoption in low-resource healthcare settings has increased by over 25%, with Asia-Pacific and Africa leading the uptake by over 15% year-on-year.

By Application 

• Bleeding Wound: In the plasma derived medicine market, treatments for bleeding wounds contribute over 10% of global application share. More than 60% of plasma used in trauma centers is applied for bleeding control. Fibrin sealants and coagulation factors are involved in over 70% of surgical wound management. Hospitals account for over 80% of bleeding wound plasma use. Usage has grown by over 30% since 2020 due to increased emergency admissions. North America alone utilizes over 45% of bleeding wound-specific plasma therapies. The adoption of plasma-derived fibrin glue has expanded by more than 25%, improving surgical recovery rates globally in the plasma derived medicine market.
• Immunodeficiency: Immunodeficiency is the largest application segment, making up over 40% of the plasma derived medicine market. Immunoglobulin therapy dominates this category, with IVIG used in over 65% of all immunodeficiency cases. Pediatric and geriatric patients contribute to more than 50% of total demand. Plasma-derived immune treatments are used in over 75% of diagnosed immune disorders. Treatment coverage has increased by over 30% globally, while hospital-based immunoglobulin infusions account for over 70% of total administration. North America and Europe together represent over 80% of immunodeficiency-related plasma therapy consumption.
• HBV (Hepatitis B Virus): Within the plasma derived medicine market, HBV applications hold more than 8% of total therapy use. Plasma-derived HBV immunoglobulins are used in over 60% of post-exposure prophylaxis cases. Asia-Pacific leads in HBV treatment, contributing over 55% of global demand. HBV-related plasma therapies are used in over 45% of liver transplant protocols. The hospital segment uses over 80% of HBV immunoglobulins for at-risk patients. Treatment protocol adherence has increased by over 35% since 2021. Preventive use of plasma-based HBV therapy in newborns accounts for over 20% of total HBV immunoglobulin distribution globally.
• Tetanus: Tetanus immunoglobulins occupy over 5% of the total plasma derived medicine market usage. Over 70% of plasma-derived tetanus treatments are used in trauma and emergency care. The demand in low-immunization regions has grown by more than 30%. Hospitals administer over 85% of tetanus plasma therapies. Usage in surgical wound cases contributes to over 25% of tetanus-specific plasma consumption. Africa and Southeast Asia make up over 50% of global tetanus immunoglobulin demand. The public health sector accounts for over 60% of administration, especially in maternal and neonatal care initiatives.
• Rabies: Rabies applications represent over 7% of the plasma derived medicine market. Plasma-based rabies immunoglobulin is used in over 65% of bite exposure cases without prior vaccination. Rural regions consume over 55% of rabies immunoglobulin supplies. Public health programs distribute over 70% of plasma-derived rabies doses. Usage in post-exposure prophylaxis has grown by more than 40% since 2022. India and parts of Africa account for over 60% of global rabies plasma demand. Hospital-based treatment dominates over 80% of usage due to strict timelines for administration post-exposure.
• Hemophilia: In the plasma derived medicine market, hemophilia holds over 25% of total application share. Over 80% of hemophilia patients are treated with plasma-derived coagulation factors. Factor VIII represents over 60% of all plasma-based clotting therapies. Hospital-based infusions cover more than 70% of treatments for moderate to severe cases. North America and Europe use over 65% of plasma therapies in hemophilia management. Plasma demand for hemophilia has grown by over 35% due to improved diagnostic coverage. Pediatric patients contribute to over 40% of the hemophilia treatment segment.
• Others: The “Others” category in the plasma derived medicine market accounts for about 5% of global usage. It includes therapies for neuromuscular disorders, Kawasaki disease, sepsis, and transplant support. More than 50% of treatments in this segment are administered in critical care units. Usage of plasma in transplant procedures has grown by over 30%. Over 25% of clinical trials for experimental plasma therapies fall under this segment. Asia-Pacific contributes to over 35% of "Others" category demand. Over 60% of these therapies are still under off-label or compassionate-use programs globally.



Request a Free sample    to learn more about this report.

Regional Outlook 

The plasma derived medicine market is regionally dominated by North America with over 50% share. Europe contributes about 25%, followed by Asia-Pacific with over 15%, and the Middle East & Africa holding below 10%. Over 60% of the world’s plasma collection facilities are based in North America. Europe utilizes over 50% of its collected plasma for immunoglobulin. Asia-Pacific shows a rising trend with over 35% increase in therapeutic adoption. Meanwhile, Middle East & Africa have improved access by over 20% through health partnerships. Regional trends collectively influence over 95% of the global plasma derived medicine market movement.

North America 

North America contributes over 50% to the global plasma derived medicine market. The U.S. alone supplies over 70% of the global plasma donation volume. Over 65% of the population with immune conditions are treated using plasma-derived immunoglobulin. Clinical trial activity in plasma products has grown by over 55%. More than 45% of fractionation facilities are based in North America. The region processes over 60% of the global plasma supply. Since 2020, therapy approvals have increased by over 25%, and patient access to IVIG has expanded by over 40%, reinforcing North America’s leadership in the plasma derived medicine market.

Europe 

Europe accounts for over 25% of the plasma derived medicine market. More than 60% of hemophilia patients in Europe rely on plasma-based clotting factors. Over 50% of albumin used in the region is administered for liver-related conditions. Germany, France, and Italy lead plasma collection, contributing over 65% of the regional total. Public healthcare systems fund over 75% of plasma therapies. EU regulations have reduced therapy approval timelines by over 20%. Plasma-related R&D in Europe has grown by over 30%, and production capacity has expanded by over 25%, ensuring strong future performance of the plasma derived medicine market.

Asia-Pacific 

Asia-Pacific contributes more than 15% to the global plasma derived medicine market and is experiencing rapid growth. China alone accounts for over 45% of regional albumin consumption. IVIG adoption has risen by over 35% across Japan, South Korea, and India. Regional plasma collection meets only 35% of demand, causing over 65% reliance on imports. Therapy usage in hospitals has increased by more than 30%. Over 25% of plasma-based treatments are for chronic liver conditions. Investments in local production have increased by over 20%, and the number of treatment centers offering plasma therapies has grown by over 40%.

Middle East & Africa 

Middle East & Africa contribute under 10% of the global plasma derived medicine market, yet growth exceeds 25% annually. Over 40% of plasma therapies are used in emergency and maternal care. Immunoglobulin use has expanded by over 35%, especially in GCC countries. Africa imports more than 70% of plasma-derived medicines. Over 50% of regional demand is met through partnerships and aid programs. South Africa and Saudi Arabia drive over 60% of market consumption in the region. Awareness campaigns have improved plasma therapy usage by more than 25%, while distribution networks have expanded by over 30%.

List of Key Plasma Derived Medicine Market Companies Profiled

• Takeda
• CSL
• Grifols
• Octapharma
• Kedrion
• LFB Group
• Biotest
• BPL
• Shanghai RAAS
• China Biologic Products
• Hualan Biological Engineering Inc.
• Beijing Tiantan Biological Products Corp
• Pacific Shuanglin
• Boya Bio-Pharmaceutical
• Paisi Feike Biology Pharmacy Co., Ltd.
• Xinjiang Deyuan Bioengineering
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
• Shenzhen Weiguang
• Shanxi Kangbao
• Nanyue Biopharming Corporation Ltd.

Top 2 Companies by Market Share

• CSL – Holds over 25% of global plasma derived medicine market share.
• Grifols – Accounts for approximately 20% of total market share.

Investment Analysis and Opportunities 

The plasma derived medicine market has seen over 60% of pharmaceutical investors shift focus toward biologics and blood-based therapies. More than 70% of new funding in 2023 and 2024 was directed into plasma fractionation plants and infrastructure. Over 55% of capital allocation went to facility expansion, while 45% supported advanced purification technologies. Investment in AI-based plasma processing tools rose by over 40%, and over 50% of global companies have adopted digitized plasma supply chain systems.

Over 35% of biotech firms are now engaged in plasma-based R&D, with over 25% of them entering partnerships to boost product development. Emerging markets account for over 30% of recent investments due to growing plasma therapy needs. More than 65% of hospitals increased plasma product inventory by over 20% during 2023–2024. Public-private partnerships represent over 15% of total investments in this sector. More than 80% of investments are aimed at expanding accessibility and improving treatment response rates. As demand increases, over 50% of companies are enhancing manufacturing capabilities to scale up supply. The plasma derived medicine market shows over 90% alignment between investor interest and long-term therapy growth, ensuring robust opportunities across all application areas.

New Products Development 

New product launches in the plasma derived medicine market have increased by over 55% between 2023 and 2024. Over 60% of these are focused on immune globulin therapies, targeting neurological and autoimmune disorders. Albumin-based innovation makes up more than 20% of new formulations, while coagulation factor products contribute over 15% to new approvals. More than 70% of new therapies emphasize faster plasma absorption and improved bioavailability.

Over 45% of clinical-stage products transitioned to commercial stage within 12 months, indicating accelerated development cycles. More than 50% of new product trials involved AI-backed molecule prediction models. Plasma substitutes now represent over 10% of experimental pipelines. Over 35% of the newly developed plasma products are optimized for subcutaneous administration, enhancing patient compliance. Over 30% of companies are integrating plasma with recombinant technologies, while 25% are exploring extended shelf-life formulations.

More than 40% of global trials focused on rare disease applications, and over 60% of orphan drugs launched in 2023–2024 had plasma-based mechanisms. Over 80% of key players have expanded their R&D portfolios in line with innovation trends. These advances reflect a plasma derived medicine market landscape where over 90% of product development is driven by clinical necessity and long-term efficacy goals.

Recent Developments by Manufacturers in Plasma Derived Medicine Market 

Between 2023 and 2024, over 65% of manufacturers in the plasma derived medicine market expanded operations. Plasma collection capacity increased by over 50%, while fractionation volumes rose by over 40%. Over 60% of regulatory filings came from top-tier companies introducing updated immune globulin and albumin therapies.

Over 55% of new approvals were for neurological and rare disease indications. More than 30% of manufacturers introduced automated collection systems. Advanced purification techniques improved plasma yield efficiency by over 35%. Supply chain automation adoption reached over 45%, streamlining distribution across more than 70% of treatment centers.

Grifols expanded capacity by over 30%, while CSL enhanced global distribution by over 25%. Over 50% of new launches were localized to meet region-specific needs. Over 40% of manufacturers began using AI-driven batch tracking systems. More than 60% of new R&D partnerships focused on enhancing plasma therapy timelines.

Over 20% of all clinical trials in 2023–2024 were centered on plasma derived medicine. Over 35% of therapy updates addressed unmet needs in hemophilia and immunodeficiency. These rapid advancements ensure the plasma derived medicine market remains over 90% innovation-driven, with strong alignment between regulatory approvals and unmet therapeutic needs.

Report Coverage of Plasma Derived Medicine Market 

The report on the plasma derived medicine market covers over 95% of the therapeutic landscape including immune globulin, albumin, coagulation factor, and others. More than 80% of the analysis is segmented by application areas such as immunodeficiency, hemophilia, HBV, tetanus, rabies, bleeding wounds, and rare diseases.

Over 50% of the regional market focus is on North America, with Europe accounting for over 25%, Asia-Pacific more than 15%, and Middle East & Africa under 10%. The report tracks over 60% of market expansions, over 45% of manufacturer strategies, and more than 70% of pipeline product developments. Over 85% of the featured companies have launched new therapies or expanded production facilities in the past two years.

The report also includes over 40% of clinical trial data linked to plasma-derived therapies, over 30% of regulatory approval trends, and over 20% of regional pricing insights. Over 90% of key industry developments since 2023 are mapped, with real-time analytics on product launches, investments, and market share dynamics. With over 70% emphasis on innovation, partnerships, and infrastructure shifts, this report gives a 100% detailed view of the fast-evolving plasma derived medicine market.